April 16, 2020 10:15 AM EDT
R&D

In­ter­im da­ta on Vir's Al­ny­lam-part­nered RNAi hep B drug sug­gest ef­fi­ca­cy is broad­ly on par with J&J, Ar­row­head ri­val — an­a­lysts

Natalie Grover

Reporter

With ef­forts un­der­way to de­vel­op an an­ti­dote for Covid-19, Vir Ther­a­peu­tics and its chief George Scan­gos, a Bio­gen vet­er­an who has been tapped to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Benev­o­len­tAI CEO is out af­ter less than a year on the job

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times